CCG
ALXN

Ceeto Capital Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Ceeto Capital Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,000
Closed -$458K – 141
2020
Q3 		$458K Hold
4,000
– – 0.26% 85
2020
Q2 		$449K Buy
+4,000
New +$425K 0.29% 83
2018
Q1 		– Sell
-5,000
Closed -$598K – 133
2017
Q4 		$598K Hold
5,000
– – 0.43% 79
2017
Q3 		$701K Buy
+5,000
New +$679K 0.53% 67

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Ceeto Capital Group's ALXN Position: Q4 2020 in Review

Ceeto Capital Group sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 4,000 shares — an estimated $458K sold.

Ceeto Capital Group first reported a position in ALXN in Q3 2017 and held it in 4 quarters. The position peaked at $701K in Q3 2017. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Ceeto Capital Group reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Ceeto Capital Group sold 4,000 Alexion Pharmaceuticals shares in Q4 2020, an estimated $458K.
  • Ceeto Capital Group first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Ceeto Capital Group's Alexion Pharmaceuticals position peaked at $701K in Q3 2017.
  • 824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Ceeto Capital Group's 13F filing for Q4 2020, filed 16 Feb 2021.